FDA needs more time to review pain medication
-
- January
- 10
Progenics Pharmaceuticals Inc., an Eastview-based biotechnology research company, and Wyeth said this morning the U.S. Food and Drug Administration needs an extra three months to review their application to market a drug to treat constipation caused by certain pain medications.
The government agency now needs until April 30 to review the application for subcutaneous methylnaltrexone, the companies said in a joint release.
The companies are developing the drug for terminally patients with conditions such as cancer or AIDS and who have taken opiods to relieve pain.
This entry was posted
on Thursday, January 10th, 2008 at 12:57 pm by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: 
| 
Print
| 
Email
